Evidence map›Paper›PMID 33154422›Full record

ArticleScientific reports2020

Influenza virus infection augments susceptibility to respiratory Yersinia pestis exposure and impacts the efficacy of antiplague antibiotic treatments.

Yaron Vagima, David Gur, Noam Erez, Hagit Achdout, Moshe Aftalion, Yinon Levy, Ayelet Zauberman, Avital Tidhar, Hila Gutman, Shlomi Lazar and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Yaron VagimaDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel. yaronv@iibr.gov.il.
David GurDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Noam ErezDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.
Hagit AchdoutDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.
Moshe AftalionDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Yinon LevyDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Ayelet ZaubermanDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Avital TidharDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Hila GutmanDepartment of Pharmacology, Israel Institute for Biological Research, Ness-Ziona, Israel.
Shlomi LazarDepartment of Pharmacology, Israel Institute for Biological Research, Ness-Ziona, Israel.
Tomer IsraelyDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.
Nir ParanDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.
Sharon MelamedDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.
Tal Brosh-NissimovInfectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
Theodor ChitlaruDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.
Irit SagiDepartment of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.
Emanuelle MamroudDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel. emmym@iibr.gov.il.
Israel Institute for Biological Research · ILAssuta Medical Center · ILWeizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various respiratory viral infections in general and seasonal influenza in particular may increase the susceptibility to bacterial infections. Plague caused by Yersinia pestis endangers large populations during outbreaks or bioterrorism attacks. Recommended antibiotic countermeasures include well-established protocols based on animal studies and corroborated by effective treatment of human cases. Until now, prior exposure to viral respiratory infections was not taken into consideration when selecting the appropriate treatment for plague. Here, we show that as late as 25 days after exposure to influenza virus, convalescent mice still exhibited an increased susceptibility to sublethal doses of Y. pestis, presented with aberrant cytokine expression, and impaired neutrophil infiltration in the lungs. Increased levels of M2 alveolar macrophages and type II epithelial cells, as well as induction in metalloproteases expression and collagen and laminin degradation, suggested that the previous viral infection was under resolution, correlating with enhanced susceptibility to plague. Surprisingly, postexposure prophylaxis treatment with the recommended drugs revealed that ciprofloxacin was superior to doxycycline in mice recovering from influenza infection. These results suggest that after an influenza infection, the consequences, such as impaired immunity and lung tissue remodeling and damage, should be considered when treating subsequent Y. pestis exposure.

Indexed as

Yersinia pestisAnimalsAnti-Bacterial AgentsCiprofloxacinDisease SusceptibilityDoxycyclineLungMacrophages, AlveolarMiceNeutrophil InfiltrationOrthomyxoviridae InfectionsPlagueTreatment OutcomeAnti-Bacterial AgentsCiprofloxacinDoxycycline

Identifiers

PMID33154422
PMCPMC7645720
OpenAlexW3095536152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.